Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1273–1296 of 17,144 matching trials from the live ClinicalTrials.gov search.
Conditions
Asthma
Interventions
Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
32
States / cities
Anaheim, California • Chula Vista, California • Fresno, California + 29 more
Conditions
Metastatic Soft-tissue Sarcoma
Interventions
Cabozantinib, Nivolumab, Ipilimumab
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Stanford, California • Aurora, Colorado • St Louis, Missouri + 1 more
Conditions
Necrotizing Enterocolitis, Intra-abdominal Infection
Interventions
meropenem
Drug
Lead sponsor
The Emmes Company, LLC
Industry
Eligibility
Up to 90 Days
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
26
States / cities
Birmingham, Alabama • Oakland, California • Orange, California + 21 more
Completed Not applicable Interventional Results available

STEM-Parkinson's Disease

NCT04797611
Conditions
Parkinson Disease, Parkinson's Disease and Parkinsonism
Interventions
TNM Device
Device
Lead sponsor
Scion NeuroStim
Industry
Eligibility
18 Years to 85 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
22
States / cities
Scottsdale, Arizona • Los Angeles, California • Englewood, Colorado + 18 more
Conditions
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
educational intervention
Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Imaging Drug FluorThanatrace (FTT)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2019 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Early Phase 1 Interventional Results available

Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia

NCT04963764
Conditions
Pneumonia, Pediatric Respiratory Diseases, Antibiotic Use, Community-acquired Pneumonia
Interventions
Amoxicillin, Placebo
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
12 Months to 71 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Cincinnati, Ohio • Philadelphia, Pennsylvania
Conditions
Colorectal Cancer
Interventions
hydroxychloroquine, entinostat, regorafenib
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Etirinotecan Pegol (NKTR-102) in NSCLC

NCT01773109
Conditions
Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer
Interventions
Etirinotecan pegol (NKTR-102)
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Juvenile Osteochondritis Dissecans
Interventions
Retro-articular drilling, Trans-articular drilling
Procedure
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 18 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • Centennial, Colorado + 9 more
Conditions
Spinal Cord Injury
Interventions
Group tele-exercise
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
23
States / cities
Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 18 more
Conditions
Advanced Solid Tumors
Interventions
MEDI1873
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 7 more
Terminated Phase 3 Interventional Results available

NET-PD LS-1 Creatine in Parkinson's Disease

NCT00449865
Conditions
Parkinson's Disease
Interventions
creatine, placebo
Drug · Other
Lead sponsor
University of Rochester
Other
Eligibility
Not listed
Enrollment
1,741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 40 more
Completed Phase 3 Interventional Results available

Phase 3 Papulopustular Rosacea Study

NCT01494467
Conditions
Papulopustular Rosacea
Interventions
CD5024, Azelaic acid 15% Gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
40
States / cities
Birmingham, Alabama • Mobile, Alabama • Hot Springs, Arkansas + 36 more
Completed Not applicable Interventional Results available

Zenith® p-Branch® Endovascular Graft Pivotal Study

NCT02396199
Conditions
Aortic Aneurysm Abdominal
Interventions
Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 21 more
Conditions
Heart Failure
Interventions
Cardiac resynchronization therapy
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
34
States / cities
Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 31 more
Conditions
Breast Cancer
Interventions
tamoxifen citrate, adjuvant therapy, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
26 Years to 120 Years · Female only
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
305
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 235 more
Conditions
Locally Advanced or Metastatic Non Small Cell Lung Cancer
Interventions
Rociletinib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
39
States / cities
Duarte, California • Fountain Valley, California • Los Angeles, California + 32 more
Conditions
Systemic Lupus Erythematosus
Interventions
Epratuzumab, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
50
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 41 more
Conditions
Obesity
Interventions
NutriSystem portion-controlled pre-packaged meals
Other
Lead sponsor
Temple University
Other
Eligibility
50 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Atopic Dermatitis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
129
States / cities
Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 100 more
Conditions
Bipolar Disorder
Interventions
Olanzapine, Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
16
States / cities
Scottsdale, Arizona • Riverside, California • San Diego, California + 13 more
Conditions
Congenital Hyperinsulinism
Interventions
Exendin (9-39), Vehicle
Drug
Lead sponsor
Diva De Leon
Other
Eligibility
Up to 12 Months
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania